ABSTRACT This study was designed to test the hypothesis of a possible role of serotonin in the pathogenesis of myocardial ischemia in patients with pure vasospastic angina, since serotonin is known to cause contraction in isolated coronary arteries. This effect, as well as serotonin-induced platelet aggregation, is reversed by ketanserin, a specific S2-receptor blocker. Five male patients (49 to 68 years old) with more than six episodes/day of myocardial ischemia at rest as characterized by ST segment elevation on the electrocardiogram (ECG) were selected for the study after a 2 day run-in period of continuous ECG Holter monitoring in the absence of any therapy except that with sublingual nitrates. In a double-blind crossover protocol they received consecutive infusions of 6 hr each of ketanserin (2 mg/hr iv, preceded by a 10 mg bolus in three patients) and placebo in the following sequence: ketanserin-placebo-ketanserin-placebo in the first and placebo-ketanserin-placebo-ketanserin in the second 24 hr period. The efficacy of the infused drug was tested by exposing platelet-rich plasma, obtained from the study patients at a fixed morning time before and during ketanserin infusions, to a series of serotonin concentrations from 10 5 to 10 8M in a conventional aggregometer. A complete suppression of aggregation curves in the range of serotonin concentrations tested resulted during administration of ketanserin. The efficacy of the drug in preventing ischemic episodes was assessed by computing the ischemic episodes (recorded by Holter monitoring) and nitroglycerin consumption in each 6 hr ketanserin period and in the corresponding placebo period. A Protocol. K (R41 468, from Janssen Pharmaceuticals, Beerse, Belgium) was available in vials of 10 mg in 2 ml of saline (5 mg/ml). Always starting at 12 A.M., patients received infusions of K and placebo (P) via a continuous infusion pump set (Valleylab IV 5000 b, Boulder, CO) precalibrated at 20 ml/ hr for consecutive periods of 6 hr each for a total period of 48 hr. Infusions were given according to the following sequence: K-P-K-P for the first and P-K-P-K for the second 24 hr period. This sequence was chosen to cover, once with the drug and once with P, identical periods over 2 consecutive days and to avoid the bias of daily spontaneous variability in the incidence of ischemic attacks. 16 K was dissolved in 500 ml of saline and the bottle was protected from light with black paper. Placebo (saline) was prepared to have the same external appearance: only a code identified the bottles, and CCU personnel were instructed to TABLE 1 change bottles in the infusion set, when required, according to the codified sequence. In addition to K or P infusions, the last three patients received a bolus (10 mg of K in 10 ml of normal saline or an identical amount of placebo) at the beginning of each infusion period. The patients' ECGs were continuously visually monitored with CCU surveillance systems and there was Holter monitoring of the two leads showing the most obvious ischemic alterations (ST segment elevation of more than 2 mm).
Different causes for coronary spasm have been postulated, including hyperactivity of the peripheral nervous system, segmental vascular hypersensitivity to humoral factors, activation of platelets at sites of atherosclerotic plaque or endothelial lesions, and release of either newly formed substances, such as thromboxane A 5 or of preformed vasoconstrictor substances, such as norepinephrine and serotonin. 6 Serotonin (5-hydroxy-tryptamine) may contract isolated coronary arteries in vitro7l9; human coronary arteries may undergo contraction by serotonin'0 and the supersensitivity of atherosclerotic arteries to ergonovine, a substance widely used in provoking vasospastic angina, " has been demonstrated to be partially mediated by interaction with serotonin receptors. 12 Actions of serotonin on blood vessels in vivo also imply indirect mechanisms, most of them commonly referred to as "amplifying effects." Among other actions serotonin amplifies blood pressure increases induced by epinephrinel3 and the vasoconstriction induced by norepinephrine. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Despite these findings, data are still lacking on the real role of serotonin, possibly from platelets, in vasospastic angina. We therefore decided to verify the working hypothesis of a role of serotonin in the vasospasm that occurs in Prinzmetal's angina using a pure antagonistic and selective serotonin vascular receptor blocker, ketanserin (K). Protocol. K (R41 468, from Janssen Pharmaceuticals, Beerse, Belgium) was available in vials of 10 mg in 2 ml of saline (5 mg/ml). Always starting at 12 A.M., patients received infusions of K and placebo (P) via a continuous infusion pump set (Valleylab IV 5000 b, Boulder, CO) precalibrated at 20 ml/ hr for consecutive periods of 6 hr each for a total period of 48 hr. Infusions were given according to the following sequence: K-P-K-P for the first and P-K-P-K for the second 24 hr period. This sequence was chosen to cover, once with the drug and once with P, identical periods over 2 consecutive days and to avoid the bias of daily spontaneous variability in the incidence of ischemic attacks. 16 K was dissolved in 500 ml of saline and the bottle was protected from light with black paper. Placebo (saline) was prepared to have the same external appearance: only a code identified the bottles, and CCU personnel were instructed to Control of the efficacy of the drug. Platelet aggregation studies were performed at the same hour (9 A.M.) on 2 consecutive days in order to process platelets exposed to P and K (fourth and eighth infusion periods, respectively). From fasting patients 9 ml of venous blood was drawn in a 10 ml polypropylene syringe filled with 1 ml sodium citrate (3.8%, pH 7.4). Platelet displacement of ST segment were also computed and heart rate was determined every 30 min. For assessment of maximum displacement of the ST segment during episodes, the following arbitrary scoring system was used: 1, episodes of from 0. 1 to 0.2 mV; 2, episodes of from 0.2 to 0.3 mV; 3, episodes of 0.3 mV or more.
Statistical analysis. Comparisons of parameter values during corresponding periods of K and P administration were performed according to the following statistical methods: for number of ischemic episodes (total, symptomatic, asymptomatic) and nitroglycerin consumption -Wilcoxon's signed rank-sum test; for duration and magnitude of ST elevation, systolic and diastolic blood pressures, and heart rate -analysis of variance.
To account for the possible influence of low drug concentration during the initial hours of K infusion in patients not receiving preload with the 10 mg bolus and for the persistence of drug effect in the initial hours of P infusion, an additional statistical analysis was performed to compare the first and the second 3 hr periods of both K and P infusions.
Results
Hemodynamic and side effects of ketanserin. Blood pressure (systolic and diastolic) and heart rate, assessed as previously described and determined without knowledge of the phase of the study were not significantly affected by either K or P. No rebound phenomenon at the discontinuation of the drug was observed. Figure 1 illustrates the behavior over time of these parameters in all five patients. No side effects of any sort were reported by any of the patients.
Effects of platelet aggregation. A virtually complete (>90%) inhibition of platelet aggregation, over the range of serotonin concentrations tested, resulted during K administration (figure 2).
Effects on ischemic episodes. Frequency of ischemic episodes (total and symptomatic, and asymptomatic by difference) and their mean duration and average maximum ST segment displacement during comparable 6 hr periods on the 2 consecutive days are reported in figure 3 together with nitroglycerin consumption. A total of 171 ischemic episodes were recorded, 33 of which (19%) were symptomatic; 94 episodes were recorded during K and 77 during P administration (NS). Subgroup (symptomatic and asymptomatic) analysis of ischemic episodes also did not reveal significant differences between P and K periods. Furthermore, no significant difference was apparent in any of the other investigated parameters (such as duration and magnitude of ST segment displacement and nitroglycerin consumption) during K and P infusions. There was also no difference found between the effects of the first and the second 3 hr periods of P and K administration, suggesting the absence of any run-in or run-off effect.
During the course of the trial one patient required nitrate infusion at the end of the first day because of a worsening of symptoms.
Discussion
On a theoretical ground platelets have multiple involvement in ischemic heart disease. Their ability to adhere to damaged endothelium or to sites of endothelial detachment has been considered one of the first pathogenic steps leading to development of atherosclerotic plaque, ' The high activity of K as an S9-receptor blocker during the infusion periods was proved by the virtually complete suppression of serotonin-induced platelet aggregation. In this context it is interesting to note that while drug concentrations at the time of sampling should be assumed, on the basis of available literature,35 to be on the order of 50 ng/ml (corresponding to 1.2 x 10-7M), the maximal serotonin concentration tested (10-5M) was still not capable of evoking any clear platelet aggregation. This finding suggests a higher receptor affinity of the drug than of the agonist itself. This was confirmed by studies in vitro of the concentration at which K inhibits platelet aggregation by serotonin 50% of the time.* The large number of ischemic episodes observed in this study allowed reasonable statistical inference. No significant difference in the number, duration or severity of ischemic episodes or ifi nitroglycerin consumption was apparent between patients on drug and those on P and, more importantly, no trend toward any variation was apparent. One patient required nitrate infusion due to an apparent worsening of symptoms. Subanalysis of differences between the first and the second halves of the drug and P infusion periods also did not demonstrate any variation from this pattern.
On the basis of our results we conclude against any practical involvement of serotonin in vasospastic angina.
